PUMA BH3 is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a Kd of 26 nM.
CAT No: R1648
PUMA BH3 is a synthetic peptide corresponding to the BH3 domain of the p53 upregulated modulator of apoptosis (PUMA), a pro-apoptotic member of the Bcl-2 protein family. As a key regulatory segment, the BH3 domain is essential for mediating protein-protein interactions that drive mitochondrial outer membrane permeabilization and subsequent apoptotic signaling. The peptide's sequence enables it to selectively bind anti-apoptotic Bcl-2 family proteins, disrupting their inhibitory effects and facilitating the activation of downstream effector proteins such as Bax and Bak. Due to these properties, PUMA BH3 is widely utilized in mechanistic studies of apoptosis, protein interaction mapping, and the development of molecular probes for cell death research.
Apoptosis research: The PUMA BH3 peptide is extensively used to elucidate the molecular mechanisms underlying programmed cell death. By mimicking the native BH3 domain, it enables researchers to dissect the specific interactions between PUMA and anti-apoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1. These studies provide valuable insights into how pro-apoptotic signals are transduced at the mitochondrial membrane and how the delicate balance of Bcl-2 family proteins determines cell fate. The peptide serves as a powerful tool in cell-free and cellular systems for probing apoptotic pathways and identifying critical regulatory nodes.
Protein-protein interaction assays: In biochemical and biophysical studies, the BH3 domain peptide is frequently employed as a probe to characterize the binding affinities and specificities of Bcl-2 family members. Techniques such as fluorescence polarization, surface plasmon resonance, and isothermal titration calorimetry benefit from the use of this peptide to quantitatively assess interactions and competitive binding events. These assays are instrumental in mapping the structural determinants of BH3-mediated binding and in validating the functional relevance of novel protein interfaces identified in high-throughput screens.
Screening of apoptosis modulators: The PUMA BH3 peptide plays a central role in high-throughput screening platforms designed to discover small-molecule inhibitors or mimetics that modulate apoptotic signaling. By serving as a template or competitor in biochemical assays, it facilitates the identification and optimization of compounds that disrupt or mimic BH3 interactions. Such screening strategies are fundamental in early-stage drug discovery, enabling the selection of candidates that selectively target anti-apoptotic proteins and modulate cell death pathways for research purposes.
Structural biology studies: Structural investigations of Bcl-2 family protein complexes often rely on the use of synthetic BH3 peptides to stabilize transient interactions for crystallographic or NMR analysis. The peptide's well-defined sequence and binding properties make it suitable for co-crystallization experiments, allowing researchers to resolve high-resolution structures of protein-peptide complexes. These structural insights are critical for understanding the conformational changes and molecular recognition events that govern apoptosis regulation at the atomic level.
Peptide-based tool development: Beyond its direct use in mechanistic studies, the PUMA BH3 peptide serves as a foundation for the design of labeled probes, affinity reagents, and functionalized derivatives. By introducing chemical modifications or conjugates, researchers can tailor the peptide for applications such as live-cell imaging, pulldown assays, or targeted delivery within experimental systems. These customized tools expand the versatility of the BH3 domain in interrogating apoptotic processes and in developing innovative approaches for cell death research.
4. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum
5. The spatiotemporal control of signalling and trafficking of the GLP-1R
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.